VASTERA
Vastera is a leading provider of web-based software products and services that facilitate international buying and selling of goods by streamlining and optimizing global trade processes. We call these products and services our solutions.
VASTERA
Industry:
Information Technology Software
Founded:
1991-11-01
Address:
Dulles, Virginia, United States
Country:
United States
Website Url:
http://www.vastera.com
Total Employee:
251+
Status:
Closed
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Data Center Products
A distributor and reseller of products and services that help integrate information technology .
Distribion
Distribion is a provider of web-based software that allows marketers to manage the complex needs of distributed marketing.
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2002-04-12 | Bergen Informatica | Bergen Informatica acquired by Vastera | N/A |
| 2002-02-25 | Imanet | Imanet acquired by Vastera | N/A |
Investors List
More informations about "Vastera"
Avstera
At Avstera, our primary initial focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients who fail to respond …See details»
About Us - Avstera
With a focus on foundational tumor biology science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment. Avstera also is proud to be collaborating with top cancer …See details»
Avstera Therapeutics - Crunchbase Company Profile & Funding
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients. Founded in 2021, with a focus on foundational science, Avstera leverages cutting …See details»
Avstera Therapeutics Corp. - LinkedIn
Avstera is a Pennsylvania based oncology-focused clinical stage biotech developing a pipeline containing immunomodulators targeting solid tumors, and a novel myeloid discovery platform …See details»
Avstera Therapeutics Company Profile 2024: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Avstera Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Avstera Therapeutics Corp. - BIO International Convention 2024
Jun 4, 2024 · With a focus on foundational tumor biology science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment, such …See details»
Avstera Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.See details»
Pipeline - Avstera
AVS200 is Avstera’s first-in-class myeloid cell therapy platform. Avstera intends to advance a lead myeloid cell therapy, designed based on the functions uncovered related to …See details»
Avstera Therapeutics Corp. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Avstera Therapeutics Corp. of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet.See details»
Avstera Therapeutics Corp. - BIO CEO & Investor Conference | BIO
Feb 7, 2023 · At Avstera, our primary focus is to address the significant unmet need of cancer patients failing to respond, or later developing resistance to existing cutting-edge …See details»
Avstera Therapeutics - Contacts, Employees, Board Members
Avstera Therapeutics has 2 current employee profiles, including Co-founder, CEO Karthik Musunuri. Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet …See details»
Newsroom - Avstera
Nov 9, 2022 · Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid TumorsSee details»
Avstera Therapeutics Corp. - BIO International Convention | BIO
Jun 7, 2023 · At Avstera, our primary focus is to address the significant unmet need of cancer patients failing to respond, or later developing resistance to existing cutting-edge …See details»
Avstera Therapeutics Corp. - CEO and Investor Conference 2025
Feb 26, 2024 · At Avstera, our primary initial focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients …See details»
Avstera Therapeutics Announces FDA Clearance of IND …
Dec 18, 2023 · AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab. Avstera …See details»
Avstera Therapeutics Announces FDA Clearance of IND …
Dec 18, 2023 · Avstera Therapeutics Corp, an oncology-focused biotech dedicated to addressing the large disease burden and significant unmet need of cancer patients, today announced the …See details»
Avstera Therapeutics Receives FDA Orphan Drug Designation on …
Nov 11, 2022 · Avstera Therapeutics Corp, an oncology-focused biotech dedicated to address the large disease burden and significant unmet need of cancer patients, has announced that the …See details»
Avstera Therapeutics Announces FDA Clearance of IND ... - BioSpace
Dec 18, 2023 · Avstera Therapeutics Corp, today announced the U.S. FDA clearance of its Investigational New Drug application (IND) for AVS100, a novel highly selective oral HDAC6 …See details»
Avstera Therapeutics Closes Seed Round to Advance its Lead …
Nov 9, 2022 · Avstera Therapeutics Corp., a biotechnology company based in the Philadelphia area, has announced the completion of its seed round to advance its lead cancer programs …See details»
Avstera Therapeutics Receives FDA Approval for IND Application …
Avstera Therapeutics Corp has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug application (IND) for AVS100, a novel oral HDAC6 …See details»